{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T03:14:15Z","timestamp":1784258055790,"version":"3.55.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["surgjournal.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgery"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.surg.2018.06.013","type":"journal-article","created":{"date-parts":[[2018,7,20]],"date-time":"2018-07-20T13:24:11Z","timestamp":1532093051000},"page":"960-964","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Characterizing parathyroid carcinomas and atypical neoplasms based on the expression of programmed death-ligand 1 expression and the presence of tumor-infiltrating lymphocytes and macrophages"],"prefix":"10.1016","volume":"164","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4992-7072","authenticated-orcid":false,"given":"Angelica","family":"Silva-Figueroa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Villalobos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle D.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Roland L.","family":"Bassett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Callisia N.","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey E.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naifa L.","family":"Busaidy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5933-1005","authenticated-orcid":false,"given":"Nancy D.","family":"Perrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.surg.2018.06.013_bib0001","first-page":"1273","article-title":"Tumors of thyroid and parathyroid glands","volume":"2","author":"Chan","year":"2013"},{"key":"10.1016\/j.surg.2018.06.013_bib0002","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1245\/s10434-016-5248-6","article-title":"Differentiating atypical parathyroid neoplasm from parathyroid cancer","volume":"23","author":"Christakis","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.surg.2018.06.013_bib0003","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1002\/jso.24407","article-title":"Oncologic progress for the treatment of parathyroid carcinoma is needed","volume":"114","author":"Christakis","year":"2016","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.surg.2018.06.013_bib0004","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.jamcollsurg.2017.01.060","article-title":"Prognostic scoring system to risk stratify parathyroid carcinoma","volume":"224","author":"Silva-Figueroa","year":"2017","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.surg.2018.06.013_bib0005","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1158\/0008-5472.CAN-15-0255","article-title":"Classifying cancers based on T-cell infiltration and PD-L1","volume":"75","author":"Teng","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.surg.2018.06.013_bib0006","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.cell.2015.03.030","article-title":"Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential","volume":"161","author":"Sharma","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.surg.2018.06.013_bib0007","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.surg.2018.06.013_bib0008","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","article-title":"PD-L1 expression as a predictive biomarker in cancer immunotherapy","volume":"14","author":"Patel","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.surg.2018.06.013_bib0009","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.surg.2018.06.013_bib0010","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1385\/EP:11:1:77","article-title":"Parathyroid adenomas with pronounced lymphocytic infiltration: no evidence of autoimmune pathogenesis","volume":"11","author":"Lam","year":"2000","journal-title":"Endocrine Pathology"},{"key":"10.1016\/j.surg.2018.06.013_bib0011","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1053\/j.seminoncol.2015.05.013","article-title":"Antagonists of PD-1 and PD-L1 in cancer treatment","volume":"42","author":"Lipson","year":"2015","journal-title":"Semin Oncol"},{"key":"10.1016\/j.surg.2018.06.013_bib0012","doi-asserted-by":"crossref","first-page":"e493","DOI":"10.14694\/EDBK_160766","article-title":"Biomarkers for immunotherapy: current developments and challenges","volume":"35","author":"Spencer","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.surg.2018.06.013_bib0013","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1245\/s10434-010-1003-6","article-title":"Clinical presentation, staging and long-term evolution of parathyroid cancer","volume":"17","author":"Talat","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.surg.2018.06.013_bib0014","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/01.cco.0000198019.53606.2b","article-title":"Parathyroid carcinoma","volume":"18","author":"Rodgers","year":"2006","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.surg.2018.06.013_bib0015","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.surg.2014.05.014","article-title":"Prognostic factors and staging systems in parathyroid cancer: a multicenter cohort study","volume":"156","author":"Villar-del-Moral","year":"2014","journal-title":"Surgery"},{"key":"10.1016\/j.surg.2018.06.013_bib0016","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/j.surg.2014.08.069","article-title":"Parathyroid carcinoma in more than 1,000 patients: a population-level analysis","volume":"156","author":"Sadler","year":"2014","journal-title":"Surgery"},{"key":"10.1016\/j.surg.2018.06.013_bib0017","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1002\/cncr.22599","article-title":"Trends in the incidence and treatment of parathyroid cancer in the United States","volume":"109","author":"Lee","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.surg.2018.06.013_bib0018","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s10549-014-2988-5","article-title":"Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer","volume":"146","author":"Muenst","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.surg.2018.06.013_bib0019","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1002\/cncr.24899","article-title":"Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma","volume":"116","author":"Hino","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.surg.2018.06.013_bib0020","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.hoc.2016.08.006","article-title":"Lung cancer biomarkers","volume":"31","author":"Villalobos","year":"2017","journal-title":"Hematol Oncol Clin North Am"},{"issue":"15, suppl","key":"10.1016\/j.surg.2018.06.013_bib0021","article-title":"Correlation of PDL1 tumor expression and outcomes in renal cell carcinoma (RCC) patients (pts) treated with pazopanib (paz)","volume":"31","author":"Figueroa","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.surg.2018.06.013_bib0022","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","article-title":"Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy","volume":"20","author":"Taube","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.surg.2018.06.013_bib0023","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1172\/JCI69219","article-title":"Radiation and immunotherapy: a synergistic combination","volume":"123","author":"Kalbasi","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.surg.2018.06.013_bib0024","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1093\/jnci\/djs629","article-title":"Combining radiotherapy and cancer immunotherapy: a paradigm shift","volume":"105","author":"Formenti","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.surg.2018.06.013_bib0025","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1146\/annurev-med-092012-112807","article-title":"Immune modulation in cancer with antibodies","volume":"65","author":"Page","year":"2014","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.surg.2018.06.013_bib0026","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nri778","article-title":"Effector and memory T-cell differentiation: implications for vaccine development","volume":"2","author":"Kaech","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.surg.2018.06.013_bib0027","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1471-2407-12-35","article-title":"Intratumoral macrophages contribute to epithelial-mesenchymal transition in solid tumors","volume":"12","author":"Bonde","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.surg.2018.06.013_bib0028","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1158\/2326-6066.CIR-15-0052","article-title":"Therapeutic peptide vaccine-induced CD8 T cells strongly modulate intratumoral macrophages required for tumor regression","volume":"3","author":"van der Sluis","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.surg.2018.06.013_bib0029","doi-asserted-by":"crossref","first-page":"20278","DOI":"10.18632\/oncotarget.4275","article-title":"Detecting cell-in-cell structures in human tumor samples by E-cadherin\/CD68\/CD45 triple staining","volume":"6","author":"Huang","year":"2015","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.surg.2018.06.013_bib0030","doi-asserted-by":"crossref","DOI":"10.4161\/21624011.2014.955346","article-title":"The ontogeny of tumor-associated macrophages: a new understanding of cancer-elicited inflammation","volume":"3","author":"Franklin","year":"2014","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.surg.2018.06.013_bib0031","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2015-2364","article-title":"CD68+ immune cells show different infiltration patterns in tissue samples from women with no clinical breast disease and those who have benign breast disease","volume":"75","author":"Arshad","year":"2015","journal-title":"Cancer Research"}],"container-title":["Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039606018303234?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039606018303234?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T09:52:38Z","timestamp":1604656358000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039606018303234"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S0039606018303234"],"URL":"https:\/\/doi.org\/10.1016\/j.surg.2018.06.013","relation":{},"ISSN":["0039-6060"],"issn-type":[{"value":"0039-6060","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterizing parathyroid carcinomas and atypical neoplasms based on the expression of programmed death-ligand 1 expression and the presence of tumor-infiltrating lymphocytes and macrophages","name":"articletitle","label":"Article Title"},{"value":"Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.surg.2018.06.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}